Microbiological analysis and whole-genome sequencing of Neisseria gonorrhoeae from the microbiological failures in the international, zoliflodacin, phase 3, clinical trial for treatment of uncomplicated urogenital gonorrhoea: a retrospective, genomic, observational studyMagnus Unemo, Alison Luckey, Esther Bettiol et al.|The Lancet Microbe|2026Cited by 4
646. Subgroup Analyses of Microbiological Cure Rates by Baseline Zoliflodacin MIC and Susceptibility to Ciprofloxacin in Participants from the Global Zoliflodacin Phase 3 Randomized Controlled TrialSarah M. McLeod, Alison Luckey, Khurram Rana et al.|Open Forum Infectious Diseases|2026Cited by 1
P-1103. In Vitro Activity of Zoliflodacin Against Baseline <i>Neisseria gonorrhoeae</i> Isolates from US Participants in a Global Phase 3 Randomized Controlled TrialSarah M. McLeod, Alison Luckey, Esther Bettiol et al.|Open Forum Infectious Diseases|2025Cited by 0
Letter to the editor regarding “Alternative drugs for the treatment of gonococcal infections: old and new” <i>Expert Review of Anti-infective Therapy</i> . 2024. 22(9):753–759Alison Luckey, Sarah M. McLeod, David Altarac|Expert Review of Anti-infective Therapy|2025Cited by 0
P-1207. In Vitro Activity of Zoliflodacin against Neisseria gonorrhoeae Isolates Collected in 2022 from The United StatesSarah M. McLeod, Alison Luckey, Meredith Hackel et al.|Open Forum Infectious Diseases|2026Cited by 0